2025 PROGRAM
The event was held at the Puerto Rico Convention Center in San Juan.
WEDNESDAY, JANUARY 15, 2025
SESSION/PRESENTATION
PRESENTER/CHAIRS
08:00 am - 08:30 am
Check-in and Breakfast
Check-in and Breakfast
08:30 am - 08:45 am
Welcome Notes
Keith Johnson, Massachusetts General Hospital, Boston, MA, USA
08:45 am - 08:55 am
Alzheimer's Association Note
Maria Carrillo, Alzheimer’s Association, Chicago, IL, USA
08:55 am - 10:35 am
SESSION I: Harmonization
Suzanne Baker, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
Bradley Christian, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
Bradley Christian, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
08:55 am - 09:00 am
Session Overview
Chairs
09:00
Longitudinal amyloid burden with combined [11C]PiB and [18F]NAV4694 PET scans
Brecca Bettcher, University of Wisconsin-Madison School of Medicine and Public Health and Waisman Center, Madison, WI, USA
09:15
Exploring Centiloids robustness: Impact of sample size and image resolution on Centiloid conversion accuracy
Jiaxiuxiu Zhang, University of California, San Francisco, San Francisco, CA, USA
09:30
Every Centiloid, from everywhere, all at once
Ganna Blazhenets, University of California, San Francisco, San Francisco, CA, USA
09:45
The Uni𝜏 ecosystem for tau-PET harmonization and visualization
Guilherme Povala, University of Pittsburgh, Pittsburgh, PA, USA
10:00
Comparative sensitivity analysis of tau-PET tracers in Alzheimer’s disease
Cécile Tissot, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
10:15 am - 10:35 am
Discussion
Discussion
10:35 am - 10:40 am
Blitz Session 1A
Blitz Session 1A
10:35 am
Introduction
10:37 am
Pathological and clinical trajectories of preclinical Alzheimer’s disease patients with divergent cortical tau patterns
Elizabeth Mormino, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, US
10:38 am
Association between early and late tau aggregation across tau imaging agents: The HEAD Study
Nesrine Rahmouni, McGill University, Montreal, QC, CA
10:39 am
Unraveling the impact of amyloid-β and tau pathology on brain structure and cognitive function during preclinical and prodromal Alzheimer’s disease
Ting Qiu, Douglas Mental Health University Institute, McGill University, Montreal, QC, CA
10:40 am - 11:35 am
Break/Poster Session 1A
Break/Poster Session 1A
11:35 am - 01:00 pm
SESSION II: Spatial Patterns
Ansel Hillmer, University of Michigan, Ann Arbor, MI, USA
Pedro Rosa-Neto, McGill University, Montreal, ON, Canada
Pedro Rosa-Neto, McGill University, Montreal, ON, Canada
11:35 am - 11:40 am
Session Overview
Chairs
11:40 am
The interaction of initial medial temporal lobe tauopathy and amyloid-beta spatial extent in driving caTAUstrophe
Michelle Farrell, Massachusetts General Hospital, Boston, MA, USA
11:55 am
Mapping spatial white matter integrity linked to tau accumulation: Insights from tractometry with multi-shell diffusion imaging
Jenna Adams, University of California Irvine, Irvine, CA, USA
12:10 pm
Spatial patterns of voxel-wise tau accumulation across the Alzheimer’s disease spectrum
Corrina Fonseca, University of California Berkeley, Berkeley, CA, US
12:25 pm
PET astroglia and microglia follow tau propagation patterns in Alzheimer’s disease
Nesrine Rahmouni, McGill University, Montreal, QC, Canada
12:40 pm - 01:00 pm
Discussion
Discussion
01:00 pm - 02:00 pm
Lunch
Lunch
02:00 pm - 02:30 pm
Keynote: From click chemistry to precision neuroscience
Hartmuth Kolb, Enigma Biomedical Group, Toronto, ON, Canada
02:30 pm - 02:45 pm
Keynote Discussion
Keynote Discussion
02:45 pm - 04:25 pm
SESSION III: Neuropath I
Tobey Betthauser, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
Teresa Gomez-Isla, Massachusetts General Hospital, Boston, MA, USA
Teresa Gomez-Isla, Massachusetts General Hospital, Boston, MA, USA
02:45 pm - 02:50 pm
Session Overview
Chairs
02:50pm
Correlation between in vivo 18F-flortaucipir PET and whole brain postmortem histological tau signals in Alzheimer’s disease
Yishu Chao, University of California Berkeley, Berkeley, CA, USA
03:05pm
Tau-PET, structural MRI, and cognitive measures are differentially correlated with tangle and neuritic pathology across the neurofibrillary tangle lifespan
Christina Moloney, Mayo Clinic, Jacksonville, FL, USA
03:20pm
Binding of [3H]MK-6240 to different tau lesions: a brain autopsy study
Milos Ikonomovic, University of Pittsburgh, Pittsburgh, PA, USA
03:35pm
Plasma extracellular vesicle TDP-43 and hippocampal volume as complementary biomarkers for LATE-NC and hippocampal sclerosis: a pathologic validation study
Michel Grothe, Reina Sofia Alzheimer Center, CIEN Foundation, Madrid, Spain
03:50pm
Discovery and preclinical development of [18F]ACI-19626, a first-in-class TDP-43 PET tracer
Francesca Capotosti, AC Immune SA, Lausanne, Switzerland
04:05 pm - 04:25 pm
Discussion
Discussion
04:25 pm - 04:30 pm
Blitz Session 1B
Blitz Session 1B
04:25 pm
Introduction
04:27 pm
Pathological asymmetry in early onset AD reflects heterogenous disease trajectories
Jacob Ziontz, Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, US
04:28 pm
Functional submodules in the human locus coeruleus are differentially susceptible to tau pathology
Timothy Lawn, Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, 02129, Boston, MA, USA, Boston, MA, US
04:29 pm
The universal tau PET scale (Uni𝜏) for Flortaucipir, MK6240, PI2620 and RO948 harmonization
Guilherme Povala, University of Pittsburgh, Department of Psychiatry, Pittsburgh, PA, US
04:30 pm - 05:25 pm
Break/Poster Session 1B
Break/Poster Session 1B
05:25 pm - 07:30 pm
THURSDAY, JANUARY 16, 2025
SESSION/PRESENTATION
PRESENTER/CHAIR
08:15 am - 08:45 am
Breakfast/Mentor Session
- Early-career challenges (Moderator TBA)
- Publishing strategies (Moderated by Dr. Gil Rabinovici)
- Start with 'Why?': Identifying impactful research projects (Moderated by Dr. Suzanne Schindler)
- Funding opportunities (Moderated by Dr. Julie Price)
- Early-career challenges (Moderator TBA)
- Publishing strategies (Moderated by Dr. Gil Rabinovici)
- Start with 'Why?': Identifying impactful research projects (Moderated by Dr. Suzanne Schindler)
- Funding opportunities (Moderated by Dr. Julie Price)
Breakfast/Mentor Session
- Early-career challenges (Moderator TBA)
- Publishing strategies (Moderated by Dr. Gil Rabinovici)
- Start with 'Why?': Identifying impactful research projects (Moderated by Dr. Suzanne Schindler)
- Funding opportunities (Moderated by Dr. Julie Price)
- Early-career challenges (Moderator TBA)
- Publishing strategies (Moderated by Dr. Gil Rabinovici)
- Start with 'Why?': Identifying impactful research projects (Moderated by Dr. Suzanne Schindler)
- Funding opportunities (Moderated by Dr. Julie Price)
08:45 am - 10:00 am
ISTAART Collaborations: Addressing Accessibility and Acceptability of Neuroimaging in Diverse Populations
Shana Stites, University of Pennsylvania, Philadelphia, PA, USA
Tobey Betthauser, University of Wisconsin, Madison, WI, USA
Tobey Betthauser, University of Wisconsin, Madison, WI, USA
08:45 am
Introduction
Reisa Sperling, Brigham and Women's Hospital/HMS, Boston, MA, USA
08:50 am
Background and collaboration
Tobey Betthauser, University of Wisconsin, Madison, WI, USA
08:55 am
A-Frame: Actionable framework for accessibility, acceptability, and alliance in aging studies using imaging
Shana Stites, University of Pennsylvania, Philadelphia, PA, USA
09:05 am
Community-engaged research for increasing representation in brain aging studies – the HABS-HD approach and lessons learned
Sid O’Bryant, University of North Texas Health Science Center, Fort Worth, TX, USA
09:15 am
Neuroimaging of older Latino adults in Boston: Linking established and new cohorts
Yakeel Quiroz, Massachusetts General Hospital, Boston, MA, USA
09:25 am – 09:55 am
Discussion
09:55 am - 10:00 am
Concluding remarks and resources
10:00 am - 10:05 am
Blitz Session 2A
Blitz Session 2A
10:00 am
Introduction
10:02 am
The role of cohort heterogeneity in predicting AD/ADRD cognitive decline
Peiwei Liu, Department of Neuroscience, University of California, Berkeley, Berkeley, CA, US
10:03 am
Sex moderates the association between regional tau and longitudinal cognitive decline in A4 and LEARN studies
Annie Li, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, US
10:04 am
Low tau in Aβ-positive cognitively impaired individuals: Alzheimer’s disease or something more?
Konstantinos Ioannou, Karolinska Institutet, Stockholm, SE
10:05 am - 11:00 am
Break/Poster Session 2A
Break/Poster Session 2A
11:00 am - 12:40 pm
SESSION IV: Neuropath II
Keith Johnson, Massachusetts General Hospital, Bonston, MA, USA
Christina Moloney, Mayo Clinic, Jacksonville, FL, USA
Christina Moloney, Mayo Clinic, Jacksonville, FL, USA
11:00 am - 11:05 am
Session Overview
Chairs
11:05 am
Understanding the mechanisms of synaptic vesicle glycoprotein 2A change in Alzheimer's disease
Laetitia Lemoine, Perceptive, London, UK
11:20 am
Association of [18F]Flortaucipir-PET and plasma p-tau217 with tau neuropathology in AD and other neurodegenerative disorders
Agathe Vrillon, University of California San Francisco, San Francisco, CA, USA
11:35 am
Tau-related cortical thinning is concentrated in sulcal depths
Samira Maboudian, University of California, Berkeley, Berkeley, CA, USA
11:50 am
Comparison of [3H]MK-6240 and [3H]AV-1451 binding in relation to brain concentrations of p-tau: A postmortem biochemistry study
Tobey Betthauser, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA
12:05 am
In vitro binding of the tau PET tracer [3H]JSS20-183A and its comparison with PI-2620, T807 and PM-PBB3 in human postmortem brain tissue
Dinahlee Saturnino Guarino, University of Pennsylvania, Philadelphia, PA, USA
12:20 pm - 12:40 pm
Discussion
Discussion
12:40 pm - 01:40 pm
Lunch
Lunch
01:40 pm - 02:10 pm
Keynote: From neuropathology to biomarkers: Novel strategies for detecting and monitoring Early Alzheimer’s disease in vivo
Lea Grinberg, University of California, San Francisco, San Francisco, CA, USA
02:10 pm - 02:25 pm
Keynote Discussion
Keynote Discussion
02:25 pm - 03:50 pm
SESSION V: Clinically Relevant Applications
Renaud La Joie, University of California, San Francisco, CA, USA
Reisa Sperling, Brigham and Women's Hospital, Boston, MA, USA
Reisa Sperling, Brigham and Women's Hospital, Boston, MA, USA
02:25 pm - 02:30 pm
Session Overview
Chairs
2:30 pm
Neuropathologic and ARIA-related findings in aducanumab-treated Alzheimer's disease: a postmortem analysis of superficial cortical Aβ clearance
Baayla Boon, Mayo Clinic, Jacksonville, FL, USA
2:45 pm
Robustness of the centiloid scale across research and commercial software using [18F]flutemetamol PET images
Adam Schwarz, GE HealthCare, Chalfont St. Giles, UK
3:00 pm
Impact of ARIA on cerebral volume changes with Gantenerumab
Matteo Tonietto, Hoffmann-La Roche, Basel, Switzerland
3:15 pm
Independent effects of baseline white matter hyperintensity and APOE ɛ4 on future ARIA-H emergence in A4 trial
Zahra Shirzadi, Massachusetts General Hospital, Brigham and Women's Hospital, HMS, Boston, MA, USA
03:30 pm - 03:50 pm
Discussion
Discussion
03:50 pm - 03:55 pm
Blitz Session 2B
Blitz Session 2B
3:50 pm
Introduction
3:52 pm
Cortical freewater increases with tau tangle aggregation
Brandon Hall, McGill University, Montreal, QC, CA
3:53 pm
Two distinct sources of 18F-MK-6240 off-target signal identified by individualized head modeling and PET kinetics
Charles Chen, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, US
3:54 pm
Tracking plasma biomarker abnormalities with amyloid time accumulation
Marina Bluma, Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Center of Alzheimer Research, Stockholm, SE
03:55 pm - 04:50 pm
Break/Poster Session 2B
Break/Poster Session 2B
04:50 pm - 06:15 pm
SESSION VI: Heterogeneity
Sylvia Villeneuve, McGill University, Montreal, QC, Canada
David Wolk, Penn Memory Center, Philadelphia, PA, USA
David Wolk, Penn Memory Center, Philadelphia, PA, USA
04:50 pm - 04:55 pm
Introduction
Chairs
4:55 pm
Improving history-based prediction of biomarker and clinical progression of autosomal dominant Alzheimer’s disease using mutation-level analysis of Aβ production
Stephanie Schultz, Harvard Medical School, Cambridge, MA, USA
5:10 pm
Tau PET load in early- and late-onset Alzheimer’s disease: A cross-sectional and longitudinal comparison of the LEADS and ADNI cohorts
Konstantinos Chiotis, University of California San Francisco, San Francisco, CA, USA
5:25 pm
Regional tau quantification methodologies in early symptomatic participants with presence of tau pathology
Leonardo Iaccarino, Eli Lilly and Company, Indianapolis, IN, USA
5:40 pm
Alpha synuclein co-pathology accelerates amyloid associated tau accumulation in Alzheimer’s disease
Nicolai Franzmeier, LMU University Hospital, Munich, Germany
Discussion
Discussion
FRIDAY, JANUARY 17, 2025
SESSION/PRESENTATION
PRESENTER/CHAIR
08:15 am - 09:00 am
Breakfast/Mentor Session
- Transitioning from Academia to Industry: Opportunities, Challenges, and Strategies (Moderated by Dr. Laetitia Lemoine)
- Multidisciplinary collaborations (Moderated by Dr. Annie Cohen)
- Translating research to clinical practice (Moderated by Drs. Renaud La Joie and David Soleimani-Meigooni)
- Research Methods and Innovations: Designing robust studies, avoiding pitfalls, and staying ahead of imaging trends (Moderated by Dr. Reisa Sperling)
- Transitioning from Academia to Industry: Opportunities, Challenges, and Strategies (Moderated by Dr. Laetitia Lemoine)
- Multidisciplinary collaborations (Moderated by Dr. Annie Cohen)
- Translating research to clinical practice (Moderated by Drs. Renaud La Joie and David Soleimani-Meigooni)
- Research Methods and Innovations: Designing robust studies, avoiding pitfalls, and staying ahead of imaging trends (Moderated by Dr. Reisa Sperling)
Breakfast/Mentor Session
- Transitioning from Academia to Industry: Opportunities, Challenges, and Strategies (Moderated by Dr. Laetitia Lemoine)
- Multidisciplinary collaborations (Moderated by Dr. Annie Cohen)
- Translating research to clinical practice (Moderated by Drs. Renaud La Joie and David Soleimani-Meigooni)
- Research Methods and Innovations: Designing robust studies, avoiding pitfalls, and staying ahead of imaging trends (Moderated by Dr. Reisa Sperling)
- Transitioning from Academia to Industry: Opportunities, Challenges, and Strategies (Moderated by Dr. Laetitia Lemoine)
- Multidisciplinary collaborations (Moderated by Dr. Annie Cohen)
- Translating research to clinical practice (Moderated by Drs. Renaud La Joie and David Soleimani-Meigooni)
- Research Methods and Innovations: Designing robust studies, avoiding pitfalls, and staying ahead of imaging trends (Moderated by Dr. Reisa Sperling)
09:00 am - 10:40 am
SESSION VII: Factors which Influence ATN
Heidi Jacobs, Massachusetts General Hospital, Boston, MA, USA
Suzanne Schindler, Washington University School of Medicine in St Louis, MO, USA
Suzanne Schindler, Washington University School of Medicine in St Louis, MO, USA
09:00 am - 09:05 am
Session Overview
Chairs
09:05
Evaluating the ATN framework in a racially and ethnically diverse cohort: Preliminary analysis from the Health Aging Brain Study- Health Disparities Study
Ann Cohen, University of Pittsburgh, Pittsburgh, PA, USA
09:20
Racial and ethnicity differences in plasma biomarker eligibility prior to amyloid PET imaging in the AHEAD 3-45 Study
Doris Molina-Henry, University of Southern California, San Diego, CA, US
09:35
Examining neighborhood disadvantage as a factor explaining amyloid onset age
Margo Heston, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
09:50
Intersections of sex and neighborhood disadvantage on Alzheimer’s disease pathology
Alexandria Reese, University of Pittsburgh, Pittsburgh, PA, USA
10:05
Sex moderates relationships between P-Tau217 and longitudinal tau-PET: A multi-cohort study
Gillian Coughlan, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
10:20 am - 10:40 am
Session Discussion
Session Discussion
10:40 am - 10:45 am
Blitz Session 3A
Blitz Session 3A
10:40 am
Introduction
10:42 am
Head-to-head comparison of longitudinal plasma assays in relation to longitudinal amyloid pathology in Alzheimer’s disease
Yara Yakoub, Douglas Mental Health University Institute, Montréal, QC, CA
10:43 am
Calibration of multi-site raters for prospective visual read of amyloid PET scans acquired across the ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI)
David Soleimani-Meigooni, Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, US
10:44 am
Plasma phosphorylated tau 217 and longitudinal trajectories of Aβ, tau, and cognition in cognitively unimpaired older adults
Hyun-Sik Yang, Brigham and Women's Hospital, Boston, MA, US
10:45 am - 11:40 am
Break/Poster Session 3A
Break/Poster Session 3A
11:40 pm - 12:40 pm
Lunch
Lunch
12:40 pm - 01:10 pm
Keynote: Alzheimer’s disease biomarkers among diverse populations – Data from the HABS-HD Study
Sid O'Bryant, The University of North Texas HSC at Fort Worth, TX, USA
01:10 pm – 01:25 pm
Keynote Discussion
Keynote Discussion
01:25 pm - 02:50 pm
SESSION VIII: Plasma Biomarkers: New Methods
Bruna Bellaver, University of Pittsburgh, PA, USA
Jasmeer Chhatwal, Massachusetts General Hospital, Boston, MA, USA
Jasmeer Chhatwal, Massachusetts General Hospital, Boston, MA, USA
01:25 pm - 01:30 pm
Session Overview
Chairs
01:30 pm
Plasma tau biomarkers and staging of Alzheimer’s disease
Gemma Salvadó, Lund University, Lund, Sweden
01:45 pm
Novel blood-based proteomic signatures across neurodegenerative diseases
Maura Malpetti, University of Cambridge, Cambridge, UK
02:00 pm
Association of CSF P-tau and MTBR-Tau biomarkers with amyloid and tau PET
Przemyslaw Kac, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
02:15 pm
VeraBIND Tau test, a novel plasma assay for active tau pathology, identifies individuals with positive F18MK6240 tau-PET signal regardless of amyloid status
Bernard Hanseeuw, Cliniques Universitaires Saint-Luc, Brussels, Belgium
02:30 pm - 02:50 pm
Session Discussion
Session Discussion
02:50 pm - 02:55 pm
Blitz Session 3B
Blitz Session 3B
02:50 pm
Introduction
02:52 pm
Locus coeruleus - medial temporal lobe functional connectivity confers protection against amyloid-related cognitive decline in the context of high cognitive reserve
Lukas Heinrich, Department of Radiology, Massachusetts General Hospital / Harvard Medical SChool, Boston, MA, US
02:53 pm
Association of a unique pattern of white matter T2 FLAIR hyperintensities with plasma and tau PET biomarkers in former American football players
Jenna Groh, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, US
02:55 pm - 03:50 pm
Break/Poster Session 3B
Break/Poster Session 3B
03:50 pm - 05:15 pm
SESSION IX: Plasma Biomarkers: Application
Bernard Hanseeuw, Cliniques Universitaires Saint-Luc, Brussels, Belgium
Hyun-Sik Yang, Brigham and Women's Hospital, Boston, MA, US
Hyun-Sik Yang, Brigham and Women's Hospital, Boston, MA, US
03:50 pm - 03:55 pm
Session Overview
Chairs
03:55 pm
Positive plasma Aβ42/40 despite negative Amyloid PET: A harbinger of progression to amyloid PET positivity?
Azadeh Feizpour, Florey Institute of Neuroscience and Mental Health, Melbourne, Australia
04:10 pm
Head-to-head association of plasma p-tau217 with MK6240, Flortaucipir, PI2620, and RO948 Tau PET Tracers
Pamela Ferreira, University of Pittsburgh, Pittsburgh, PA, USA
04:25 pm
Modeling the temporal progression of plasma and PET AD biomarkers with cognition
Petrice Cogswell, Mayo Clinic, Rochester, MN, USA
04:40 pm
Comparison of amyloid PET, tau PET, and pTau217 biomarker progression between Down syndrome and neurotypical adults with sporadic Alzheimer’s disease
Matt Zammit, University of Wisconsin, Madison, WI, USA
04:55 pm - 05:15 pm
Session Discussion
Session Discussion
05:15 pm - 05:30 pm
Awards Ceremony
Awards Ceremony
05:30 pm
Concluding Remarks
Keith Johnson, Massachusetts General Hospital, Boston, MA, USA